Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases. Headquartered in Palo Alto, California, the company utilizes its proprietary Antibody Biopolymer Conjugate (ABC) platform to design treatments for high-prevalence ophthalmic conditions. Its clinical pipeline includes biologic drug candidates such as Zenkuda (tarcocimab tedromer), KSI-501, and KSI-101, which target diseases like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. By conjugating biologics such as antibodies with biopolymers, Kodiak aims to create therapies that offer extended durability and improved efficacy compared to existing treatments. The company operates primarily in the United States and partners with healthcare institutions to advance its clinical trials.
